Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anupam Verma

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Nitric Oxide : Biology and Chemistry|January 12, 2010
Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generationSatyananda Patel, Sachin Kumar, Anupam Jyoti, et al.
Blood Advances|September 25, 2024
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trialMarisol Betensky, Maua Mosha, Cristina Tarango, et al.
Kidney International Reports|July 18, 2025
Randomized Double-Blind Placebo-Controlled Trial of Desmopressin for Post-Kidney Biopsy BleedingNarayan Prasad, Jeyakumar Meyyappan, Deependra Kumar Yadav, et al.
Research and Practice in Thrombosis and Haemostasis|December 3, 2024
Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational TrialGary M Woods, Alexandra Miller, Maua Mosha, et al.
BMC Health Services Research|November 6, 2023
Vaccination practices of pediatric oncologists from eight statesKarely M van Thiel Berghuijs, Heydon K Kaddas, Echo L Warner, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Leukemia|February 26, 2020
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemiaFranco Locatelli, James A Whitlock, Christina Peters, et al.
Pediatric Hematology and Oncology|April 28, 2020
A phase I study of panobinostat in children with relapsed and refractory hematologic malignanciesJohn Goldberg, Maria Luisa Sulis, Julia Bender, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
<i>CRLF2</i>-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySara K Silbert, Samantha Scanlon, Hao-Wei Wang, et al.
Blood Advances|October 22, 2025
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual DiseaseJason N Berman, Anupam Verma, Shelton A Viola, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Nitric Oxide : Biology and Chemistry|January 12, 2010
Nitric oxide donors release extracellular traps from human neutrophils by augmenting free radical generationSatyananda Patel, Sachin Kumar, Anupam Jyoti, et al.
Blood Advances|September 25, 2024
Outcomes in children with provoked venous thrombosis and antiphospholipid antibodies: findings from the Kids-DOTT trialMarisol Betensky, Maua Mosha, Cristina Tarango, et al.
Kidney International Reports|July 18, 2025
Randomized Double-Blind Placebo-Controlled Trial of Desmopressin for Post-Kidney Biopsy BleedingNarayan Prasad, Jeyakumar Meyyappan, Deependra Kumar Yadav, et al.
Research and Practice in Thrombosis and Haemostasis|December 3, 2024
Clinical characteristics, treatment, and outcomes of provoked acute cerebral sinovenous thrombosis in patients <21 years old: findings from the Kids-DOTT Multinational TrialGary M Woods, Alexandra Miller, Maua Mosha, et al.
BMC Health Services Research|November 6, 2023
Vaccination practices of pediatric oncologists from eight statesKarely M van Thiel Berghuijs, Heydon K Kaddas, Echo L Warner, et al.
Cancers|February 10, 2024
Nivolumab Plus 5-Azacitidine in Pediatric Relapsed/Refractory Acute Myeloid Leukemia (AML): Phase I/II Trial Results from the Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) ConsortiumAnupam Verma, Yueh-Yun Chi, Jemily Malvar, et al.
Leukemia|February 26, 2020
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemiaFranco Locatelli, James A Whitlock, Christina Peters, et al.
Pediatric Hematology and Oncology|April 28, 2020
A phase I study of panobinostat in children with relapsed and refractory hematologic malignanciesJohn Goldberg, Maria Luisa Sulis, Julia Bender, et al.
Journal for Immunotherapy of Cancer|October 26, 2024
<i>CRLF2</i>-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySara K Silbert, Samantha Scanlon, Hao-Wei Wang, et al.
Blood Advances|October 22, 2025
Molecular Risk Markers Define Risk of Relapse in Myeloid Leukemia of Down syndrome Beyond Measurable Residual DiseaseJason N Berman, Anupam Verma, Shelton A Viola, et al.
Pageof 8